Paid Clinical Trials Paid Clinical Trials > Browse Categories > Medications / Interventions > Bb > Blood Substitutes

Blood Substitutes

Blood Substitutes

All Categories Medications / Interventions » Bb » Blood Substitutes



  • Condition:   Blepharitis
    Interventions:   Drug: povidone iodine;   Drug: Povidone-Iodine;   Drug: Azithromycin;   Drug: tobramycin-dexmethasone
    Sponsors:   Southern California Institute for Research and Education;   Southern California Institute for Research and Education
    Recruiting - verified March 2012

  • Conditions:   Blood Donor;   Leukocyte Transfusion;   Granulocyte Colony-Stimulation Factor;   Blood Component Removal
    Interventions:   Drug: Filgrastim (G-CSF);   Drug: Dexamethasone
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
    Recruiting - verified February 2012

  • Condition:   Multiple Myeloma
    Interventions:   Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan);   Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan);   Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12);   Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
    Sponsors:   University of Iowa;   University of Iowa;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012

  • Conditions:   Shoulder Pain;   Injury of Shoulder Region;   Disorder of Shoulder;   Disorder of Rotator Cuff;   Disorder of Tendon of Biceps
    Interventions:   Drug: Dexamethasone;   Drug: Bupivacaine
    Sponsors:   Lifespan;   Lifespan;   Tufts Medical Center;   United States Naval Medical Center, Portsmouth
    Not yet recruiting - verified March 2012

  • Conditions:   Keratoconus;   Corneal Ectasia
    Interventions:   Drug: Riboflavin;   Drug: Riboflavin
    Sponsors:   Cornea and Laser Eye Institute;   Cornea and Laser Eye Institute
    Recruiting - verified November 2011

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: Budesonide;   Drug: Placebo;   Procedure: Procedure/Surgery: Blood sampling, endoscopy
    Sponsors:   Santarus;   Santarus
    Recruiting - verified May 2012

  • Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified April 2012

  • Condition:   Acromegaly
    Intervention:   Other: Oral Glucose Tolerance Test (OGTT)
    Sponsors:   Cedars-Sinai Medical Center;   Cedars-Sinai Medical Center
    Recruiting - verified June 2011

  • Condition:   Acute Kidney Injury
    Interventions:   Drug: ATG;   Drug: Rituximab;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Hydrocortisone;   Drug: Prednisone
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified August 2011

  • Condition:   Breast Cancer
    Intervention:   Other: MRI
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2012

  • Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Sarcoma;   Desmoplastic Small Round Cell Tumor
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Biological: NK-DLI Infusions
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012

  • Condition:   Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: fludarabine phosphate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified April 2012

  • Condition:   Type 2 Diabetes
    Interventions:   Drug: liraglutide;   Drug: insulin detemir;   Drug: liraglutide plus insulin detemir
    Sponsors:   Indiana University;   Indiana University;   Novo Nordisk
    Recruiting - verified June 2011

  • Conditions:   Arthroplasty, Knee Replacement;   Replacement, Total Knee;   Total Knee Replacement
    Interventions:   Drug: Swab area with Betadine;   Drug: Swab area with ChloraPrep
    Sponsors:   Central DuPage Hospital;   Central DuPage Hospital
    Recruiting - verified February 2012

  • Condition:   Breast Cancer
    Interventions:   Drug: Anastrozole;   Drug: ADZ0530;   Drug: Placebo;   Procedure: Pharmacokinetic studies;   Procedure: Definitive Surgery;   Procedure: Core Biopsy;   Genetic: Tumor Tissue Collection for Genetic and Molecular Studies
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center;   Doris Duke Charitable Foundation
    Recruiting - verified October 2011

  • Condition:   Menopause
    Interventions:   Drug: estradiol transdermal system;   Drug: Amino acid;   Drug: Placebo Patch;   Drug: Placebo
    Sponsors:   University of Pennsylvania;   University of Pennsylvania;   National Institute on Aging (NIA)
    Recruiting - verified January 2012

  • Conditions:   Testosterone;   Trauma;   Brain Injury
    Interventions:   Drug: Androgel (Testosterone Gel);   Drug: Androgel Placebo
    Sponsors:   Craig Hospital;   Craig Hospital;   University of Colorado, Denver
    Recruiting - verified February 2012

  • Conditions:   Keratoconus;   Corneal Ectasia
    Interventions:   Drug: Riboflavin/Dextran;   Drug: Hypotonic Riboflavin
    Sponsors:   Cornea and Laser Eye Institute;   Cornea and Laser Eye Institute
    Recruiting - verified November 2011

  • Condition:   Menorrhagia
    Interventions:   Drug: Estradiol 30 mcg / Levonorgestrel 150 mcg monophasic oral contraceptive pills;   Drug: Naproxen sodium pills;   Device: Nova Sure Radiofrequency Endometrial Ablation
    Sponsors:   Mayo Clinic;   Mayo Clinic;   Hologic, Inc.
    Recruiting - verified January 2012

  • Condition:   PCOS
    Interventions:   Drug: Dexamethasone and recombinant hCG;   Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
    Sponsors:   University of California, San Diego;   University of California, San Diego;   University of Virginia
    Recruiting - verified August 2011

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: bendamustine hydrochloride;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Drug: etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified May 2012

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone;   Drug: Lenalidomide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified March 2012

  • Conditions:   Metabolic Diseases;   Diabetes Mellitus;   Endocrine System Diseases;   Glucose Metabolism Disorders
    Interventions:   Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation;   Drug: Administration of Aliskiren, Spironolactone, or Placebo;   Drug: Increased Dose, Combination, or Placebo
    Sponsors:   Vanderbilt University;   Vanderbilt University
    Recruiting - verified August 2011

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: double-unit umbilical cord blood transplantation;   Other: cytogenetic analysis;   Procedure: bone marrow aspiration;   Other: fluorescence in situ hybridization;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: anti-thymocyte globulin;   Drug: methylprednisolone;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
    Recruiting - verified January 2012

  • Condition:   Asthma
    Intervention:   Drug: 10 mg tablet of montelukast (Singulair)
    Sponsors:   Nemours Children's Clinic;   Nemours Children's Clinic;   Merck
    Recruiting - verified November 2011

  • Condition:   Kidney Transplant
    Interventions:   Drug: Tacrolimus;   Drug: Sirolimus (Rapamune, Rapamycin);   Drug: Mycophenolate Mofetil + Prednisone
    Sponsors:   Mayo Clinic;   Mayo Clinic;   Wyeth is now a wholly owned subsidiary of Pfizer
    Recruiting - verified December 2011

  • Conditions:   Advanced Non-small Cell Lung Cancer;   Postmenopausal Women
    Interventions:   Drug: fulvestrant (Faslodex);   Drug: anastrozole (Arimidex);   Drug: Bevacizumab (Avastin);   Drug: Best standard of care
    Sponsors:   University of Pittsburgh;   University of Pittsburgh
    Recruiting - verified January 2012

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: cytarabine;   Drug: decitabine;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011

  • Conditions:   Obesity;   Hypertension
    Interventions:   Drug: eplerenone, amlodipine;   Drug: eplerenone;   Drug: eplerenone;   Drug: amlodipine
    Sponsors:   University of Mississippi Medical Center;   University of Mississippi Medical Center
    Recruiting - verified April 2012

  • Conditions:   Lung Injury, Acute (ALI);   Respiratory Distress Syndrome, Acute (ARDS)
    Interventions:   Drug: 5% human albumin;   Drug: 6% hetastarch
    Sponsors:   Emory University;   Emory University;   Food and Drug Administration (FDA)
    Recruiting - verified June 2011

  • Condition:   Posttraumatic Stress Disorder
    Interventions:   Procedure: MRI of the pituitary;   Procedure: DEX/CRH test
    Sponsors:   Cedars-Sinai Medical Center;   Cedars-Sinai Medical Center
    Recruiting - verified December 2008

  • Condition:   Leukemia
    Interventions:   Biological: filgrastim;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   University of Pittsburgh;   University of Pittsburgh
    Recruiting - verified May 2012

  • Condition:   Polycystic Ovary Syndrome
    Interventions:   Drug: ganirelix acetate;   Drug: methyl testosterone
    Sponsors:   Yale University;   Yale University
    Recruiting - verified August 2011

  • Condition:   Allogeneic Stem Cell Transplantation
    Intervention:   Drug: Genotropin (Recombinant Human Growth Hormone)
    Sponsors:   Duke University;   Duke University;   Pfizer
    Recruiting - verified November 2011

  • Condition:   Autoimmune Disorder
    Interventions:   Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified January 2012

  • Condition:   Ovarian Cancer
    Intervention:   Drug: flutamide
    Sponsors:   University of Arizona;   University of Arizona;   National Cancer Institute (NCI)
    Recruiting - verified September 2010

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Procedure: Bone marrow aspiration and biopsy;   Procedure: Apheresis
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2012

  • Condition:   Obesity
    Interventions:   Behavioral: meal test and intravenous catheter placement;   Other: Observational;   Other: intravenous catheter placement and blood collection
    Sponsors:   Columbia University;   Columbia University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified January 2012

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011

  • Conditions:   Neutropenia;   Infection
    Interventions:   Drug: Standard antimicrobial therapy;   Biological: Granulocyte transfusions;   Drug: G-CFS/dexamethasone;   Device: Apheresis machine
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2011

  • Condition:   Graft Versus Host Disease
    Interventions:   Procedure: Photopheresis;   Drug: Methylprednisolone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
    Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
    Recruiting - verified December 2011

  • Condition:   Burns
    Interventions:   Procedure: Stable Isotope Infusion Study;   Procedure: Collection of blood and tissues;   Procedure: Radiology testing: DEXA, K+ counter, ultrasound, MRI;   Drug: Humatrope;   Drug: Ketoconazole;   Drug: Oxandrolone;   Drug: Propranolol;   Drug: Oxandrolone and propranolol combined;   Drug: Humatrope and propranolol combined;   Drug: Placebo;   Behavioral: Exercise--Hospital supervised intensive exercise program;   Behavioral: Home exercise program
    Sponsors:   The University of Texas, Galveston;   The University of Texas, Galveston;   U.S. Department of Education;   National Institutes of Health (NIH);   Shriners Hospitals for Children
    Recruiting - verified March 2012

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified June 2011

  • Conditions:   Prostate Cancer;   Pain
    Interventions:   Drug: Azacitidine;   Drug: Docetaxel;   Drug: Prednisone;   Genetic: Azacitidine induced demethylation of repetitive elements.;   Genetic: GADD45α methylation and expression in prostate cancer tissue;   Genetic: GADD45α methylation in serum DNA
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified March 2012

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: anti-thymocyte globulin (ATG);   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor;   Drug: Dexamethasone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012

  • Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
    Recruiting - verified October 2008